scholarly journals Photoprotection according to skin phototype and dermatoses: Practical recommendations from an expert panel

Author(s):  
T. Passeron ◽  
H.W. Lim ◽  
C‐L. Goh ◽  
H.Y. Kang ◽  
F. Ly ◽  
...  
Infection ◽  
2017 ◽  
Vol 45 (2) ◽  
pp. 249-249
Author(s):  
Roberto Ranieri ◽  
◽  
Giulio Starnini ◽  
Sergio Carbonara ◽  
Emanuele Pontali ◽  
...  

Infection ◽  
2016 ◽  
Vol 45 (2) ◽  
pp. 131-138 ◽  
Author(s):  
Roberto Ranieri ◽  
◽  
Giulio Starnini ◽  
Sergio Carbonara ◽  
Emanuele Pontali ◽  
...  

2020 ◽  
Vol 53 (4) ◽  
pp. 216-222
Author(s):  
Ronaldo Hueb Baroni ◽  
Tufik Bauab Jr. ◽  
Leonardo Kayat Bittencourt ◽  
Giuseppe D’Ippolito ◽  
Suzan Menasce Goldman ◽  
...  

Abstract Objective: To assess the practical aspects of the use of various gadolinium-based contrast agents (GBCAs) by radiologists. Materials and Methods: Ten experienced radiologists from different regions of Brazil participated in a Delphi panel querying their use of various GBCAs, including linear and macrocyclic classes (1.0 and 0.5 M), in terms of the choice of agent, volume and dosage of the agents, and associated safety concerns. Results: The response rate was 100% for all questions. GBCAs are safe in terms of acute adverse reactions, and nephrogenic systemic fibrosis is rare. The deposition of gadolinium in the brain and other tissues is a concern among the experts. Macrocyclic agents are preferable to linear agents; an injection volume below 0.1 mL/kg of a 1.0 M agent could result in good-quality images with additional long-term safety, but there is no published evidence to support this recommendation. The majority of experts preferred not to administer GBCAs to pregnant patients. Conclusion: When choosing a GBCA, it is important to consider the characteristics of the gadolinium deposition in patient tissues and minimize potential risks. Furthermore, medical education programs are needed to increase the awareness of the potential risks of gadolinium deposition and thus avoid instances of overexposure to the contrast agent.


2019 ◽  
Vol 3 (6) ◽  
pp. 368-373
Author(s):  
Quinn Thibodeaux ◽  
Rick Fried ◽  
Gary Goldenberg ◽  
George Han ◽  
Sylvia Hsu ◽  
...  

Psoriasis patients with comorbid depression represent a common therapeutic challenge for dermatologists. Depressed patients often require the practicing dermatologist to go outside of their comfort zone, and the FDA’s labeling of medications such as brodalumab have further complicated an already difficult-to-treat patient population. A multi-disciplinary work-group consisting of a board-certified psychiatrist, a licensed clinical psychologist, and multiple dermatologists was convened to formulate practical recommendations for the evaluation and treatment of this at-risk population. How to broach the subject of depression and when to refer patients for formal evaluation were discussed. The expert panel also produced a consensus statement regarding the use of brodalumab in patients with both psoriasis and depression.  


2015 ◽  
Vol 13 (12) ◽  
pp. 1240-1249 ◽  
Author(s):  
Wolfgang G. Philipp-Dormston ◽  
Sigrid Karrer ◽  
Holger Petering ◽  
Claas Ulrich ◽  
Thomas Dirschka ◽  
...  

2005 ◽  
Vol 38 (14) ◽  
pp. 54
Author(s):  
MITCHEL L. ZOLER
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document